Evaluation of Intravitreal injection of Bevacizumab for treatment of Chronic Central Serous Chorioretinopathy
- Conditions
- chronic central serous chorioretinopathy.Disease of the eye and adnexa
- Registration Number
- IRCT201202198983N1
- Lead Sponsor
- Guilan Universoty of Medical Sciences, Pro-vice-chancellor for resea
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 15
Inclusion criteria :
1- patient by Acute Central Serous Chorioretinopathy for more than 4-months.
2- Comformation of The Chronic Central Serous Chorioretinopathy byOcular Coherent Tomography(OCT) and Fluorescien Angiography (FFA) .
3- comfirmation of the Diseasis by Supervisor of Study.
Exclusion criteria:
1- Chronic Central Serous Chorioretinopathy more than 2 years.
2- History of Treatment by any type of Laser.
3-History of Thromboambolic Diseasis Like Myocardial Infarction and Cerebro Vascular accident.
4- History of Treatment by Intravitreal Avastin during 2 months ago.
5- any sistemic Diseasis that need Oral Corticosteroid Thrapy.
6- un - Controled Glaucoma
7- Pregnancy
8- Lack of agreement by Patient for periodic Follow up during study.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Vision Improvement. Timepoint: every 6 to 8 weeks untill 6 month. Method of measurement: Snelen Chart.;Anatomical Improvement. Timepoint: every 6 to 8 weeks untill 6 month. Method of measurement: Clinical exam and OCT.
- Secondary Outcome Measures
Name Time Method Centeral thickness of retin. Timepoint: per 6-8 weeks till 6 month. Method of measurement: with OCT.If in the first examination( by OCT) after weeks 6 to 8 ,at least 10 % reduction in the central macular thickness occur,the patient will be periodically follow,if not ,the patient will be omitted.